Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: P53 Mutation Clear all
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jun 25, 2026, 6:54 AM EDT
Not listed Phase 1Phase 2 Interventional

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
TL-895, KRT-232
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

NCT04452292
View directory record Official record
Conditions
Large-Cell Neuroendocrine Carcinoma
Interventions
Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma, Treatment for Small Cell Lung Cancer
Other
Lead sponsor
Charles Kunos
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 25, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

NCT03940352
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions
HDM201, MBG453, Venetoclax
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 25, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Monitoring in TP53 Mutation Carriers

NCT02289326
View directory record Official record
Conditions
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jun 25, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

NCT02203513
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions
LY2606368
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

NCT02143635
View directory record Official record
Conditions
Advanced Solid and Hematological TP53wt Tumors
Interventions
HDM201, ancillary treatment
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jun 25, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

NCT03641313
View directory record Official record
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy, Irinotecan, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
31
States / cities
Duarte, California • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

NCT03931291
View directory record Official record
Conditions
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Interventions
APR-246
Drug
Lead sponsor
Aprea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jun 25, 2026, 6:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NCT01443468
View directory record Official record
Conditions
Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Redondo Beach, California • Fort Wayne, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 25, 2026, 6:54 AM EDT
Recruiting No phase listed Observational

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

NCT04541654
View directory record Official record
Conditions
Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

NCT03063203
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult
Interventions
Decitabine, Bone marrow biopsy/aspirate, Peripheral blood draw, Skin biopsy, Buccal swab
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jun 25, 2026, 6:54 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

NCT07646821
View directory record Official record
Conditions
Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
Interventions
ropeginterferon alfa- 2b, Azacitidine (AZA)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

NCT04358393
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Interventions
APG-115, 5-azacitidine
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Gilbert, Arizona • Denver, Colorado • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jun 25, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
4
States / cities
Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058
View directory record Official record
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jun 25, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
220
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 173 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

NCT02909972
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ALRN-6924, ALRN-6924 in combination with cytarabine
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 25, 2026, 6:54 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

NCT06690281
View directory record Official record
Conditions
Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
Interventions
KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 25, 2026, 6:54 AM EDT
Recruiting Phase 1 Interventional

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
Interventions
Autologous, engineered T Cells targeting TP53 R175H
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 25, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

NCT02337829
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib (Arm A), Acalabrutinib (Arm B)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 25, 2026, 6:54 AM EDT